Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

EXTON, Pa., Feb. 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2010.

In 2010, we:

  • Achieved a record $439 million in annual net product sales, including $177 million in net sales of Cinryze® (C1 esterase inhibitor [human]);
  • Attained non-GAAP adjusted net income of $157 million, representing 88 percent growth over the prior year; GAAP net income reached $126 million;
  • Delivered positive cash flows from operations of $194 million; and
  • Improved working capital to $561 million as of December 31, 2010, including cash, cash equivalents and short-term investments of $505 million;

  • Net sales were $121.6 million and $439.0 million for the fourth quarter and year ended December 31, 2010, respectively, as compared to $87.8 million and $310.4 million in the comparative periods of 2009, respectively.  This represents 38 percent growth in the fourth quarter and 41 percent growth for the year in net product sales.

    "2010 was an outstanding year for ViroPharma, and by focusing on the needs of our patients we were able to achieve excellent financial results," stated Vincent Milano, ViroPharma's chief executive officer.  "I'm proud of the work that our team did in 2010 to improve the lives of patients suffering from life threatening illnesses including hereditary angioedema.  Our work in 2011 will continue to build upon these efforts to foster brand loyalty by listening and responding to the needs of our patients, enhancing our patient support tools, providing an additional mode of administration of Cinryze, and globalizing the Cinryze experience.  On that topic, I am pleased to announce that we have recently submitted our responses to our European MAA Day 180 questions, and remain confident in our ability to gain Eur
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... , March 5, 2015  UBM Medica US ... a leading online community to help oncologists and ... newest information available regarding the use of targeted ... cancer. March is National Kidney ... few effective adjuvant treatment options for renal cell ...
    (Date:3/5/2015)... Chardon, Ohio (PRWEB) March 05, 2015 ... and Gold Development Partner located in Northeast Ohio, today ... chosen e2b teknologies to support its upgrade to the ... As the largest independent group practice of its kind ... base and large volume of transactions, so efficiency and ...
    (Date:3/4/2015)... VILLAGE, Nev. , March 4, 2015 PDL BioPharma, ... the adjusted conversion rate for the: , 3.75% ... is 174.8506 shares of common stock per $1,000 principal amount ... The conversion rate for the note is adjusted in ... paid on March 12, 2015, to all stockholders who own shares ...
    (Date:3/4/2015)... BROOKLYN, N.Y. , March 4, 2015  Brooklyn ... treat their acute and chronic pain and injuries. ... to announce the grand opening of his NJS Physical ... NY on Thursday, March 5, 2015. Health ... the facility, which is located at 1178 Flatbush Avenue. ...
    Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
    ... CALGARY, March 13 /PRNewswire-FirstCall/ - SemBioSys Genetics ... portfolio of therapeutic,proteins for metabolic and cardiovascular ... European patent EP0986309(B1) entitled "Uses of Oil,Bodies". ... which has exclusively,licensed commercial rights associated with ...
    ... long,been known for its amber waves of grain ... however, is that Kansas, agricultural,expertise has catapulted it ... namely, the scientific laboratory., That,s right. Kansas, ... positioned the state squarely in the forefront,of some ...
    ... Full Year Net Income up 283.0%, SHANGHAI, China, ... WX ), the leading global pharmaceutical,biotechnology and medical device ... unaudited financial results for the,fourth quarter and full year ... Highlights:, Compared to the fourth quarter 2006 results, ...
    Cached Biology Technology:SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office 2SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office 3Op-Ed: The NBAF Would Build on Kansas' Existing Strengths in Bioscience 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 12
    (Date:2/19/2015)... .19, 2015 Research and Markets ... the "Military Electro-Optical / Infrared Systems Market ... Platform - Forecast to 2020" report to ... systems market is expected to reach $16.35 billion ... This report segments the military electro-optical/infrared ...
    (Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
    (Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
    Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
    ... La. Dr. Yuri Lvov, professor of chemistry and ... Louisiana Tech University, recently led a symposium at the ... his application of a more eco-friendly and cost-effective nano-material ... of plastics, paints and other synthetic composites. The ...
    ... be used as tiny shuttles to deliver genes to ... way than was possible in the past. But ... medicine, concerns have arisen about their potential toxicity. ... toxicity rely on the ability of scientists to quantify ...
    ... critical tasks that a dividing cell must accomplish is the ... each new daughter cell. Now, a study published by Cell ... Cell , provides fascinating new insight into the complex of ... cell division. During the process of mitosis, DNA ...
    Cached Biology News:Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference 2 Inverting a standard experiment sometimes produces different results 2 Inverting a standard experiment sometimes produces different results 3New insight into chromosome segregation: Centromere-independent kinetochore assembly 2
    ... This adapter allows the ... and AB-1000) PCR plates ... the ABI PRISM® 3700 ... ABgene® for information on ...
    Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
    Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
    ... White lyophilized solid. PROTECT FROM LIGHT. ... inhibitor of γ-secretase. Equipotently inhibits the release ... = 2.6 μM) and Aβ x-42 ... HEK293 cells stably transfected with the Amyloid ...
    Biology Products: